Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial

OBJECTIVE: The aim of this study was to investigate long-term clinical outcomes of extended treatment with CT-P10, a rituximab biosimilar, compared with rituximab reference products sourced from the USA and the EU (US-RTX and EU-RTX) in rheumatoid arthritis (RA) for up to 48 weeks. METHODS: In this...

Descripción completa

Detalles Bibliográficos
Autores principales: Suh, Chang-Hee, Yoo, Dae Hyun, Berrocal Kasay, Alfredo, Chalouhi El-Khouri, Elia, Cons Molina, Francisco Fidenci, Shesternya, Pavel, Miranda, Pedro, Medina-Rodriguez, Francisco G., Wiland, Piotr, Jeka, Slawomir, Chavez-Corrales, Jose, Linde, Thomas, Hrycaj, Pawel, Abello-Banfi, Mauricio, Hospodarskyy, Ihor, Jaworski, Janusz, Piotrowski, Mariusz, Brzosko, Marek, Krogulec, Marek, Shevchuk, Sergii, Calvo, Armando, Andersone, Daina, Park, Won, Shim, Seung Cheol, Lee, Sang Joon, Lee, Sung Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373391/
https://www.ncbi.nlm.nih.gov/pubmed/30719632
http://dx.doi.org/10.1007/s40259-018-00331-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373391/
https://www.ncbi.nlm.nih.gov/pubmed/30719632
http://dx.doi.org/10.1007/s40259-018-00331-4

Ejemplares similares